Abstract Category: 13. Heart Failure: Therapy Presentation Number: 1229-599 Authors: J. Malcolm O. Arnold, Haissam Haddad, Andrew Ignaszewski, Annemarie Kaan, Peter Liu, Michael Chan, Marie LeBlanc, Jonathan Howlett, Gord Marchiori, London Health Sciences Centre, London, Canada Background: Patients with chronic heart failure (HF) are at increased risk of hospitalization and death. Large randomized clinical trials have shown clinical benefit in selected populations of HF patients. However, effective drugs may have different utilization and outcomes in the 'real world' that includes older and more fragile patients.
Methods:
The Canadian Heart Failure Network (CHFN) of 28 centers, with experienced HF doctors and nurses, has documented the clinical course and drug utilization in 18,448 HF outpatients. We describe the utilization of HF medications by age [<80yrs (n=15,729) versus >80yrs (n=2719)] at the time of their first CHFN clinic visit.
Results:
The table shows utilization of medications by age at first CHFN clinic assessment with an available BP. BP (mean (sd)) was 117.9 (21.8)/69.9 (12.1) mmHg in patients <80yrs old and 122.8 (22.6)/66.4 (11.3) mmHg in patients >80yrs old.
Medications
Age Conclusions: Although HF patients aged >80 yrs are at greater cardiovascular risk, at first documentation in this large outpatient database, evidence based HF medications are used significantly less often than in patients <80yrs. In contrast, furosemide and vasodilators are used more often. As increased use of diuretics and vasodilators did not lower mean BP's in patients >80yrs, there remains an opportunity to increase evidenced based medicines to stabilize the HF syndrome, though serum creatinine was higher in patients >80yrs (137+/-66mol) vs<80yrs (117+/-76mol/l).
